Biogen (BIIB) | Financial Analysis & Statements

Biogen Inc. | Large-cap | Healthcare

$130.13

-2.06%

Biogen vs Eli Lilly and Biogen vs Johnson & Johnson Biogen vs Merck & Co Biogen vs Amgen Biogen vs Gilead Sciences Biogen vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 9.7B

Gross Profit 7.4B 76.12%

Operating Income 2.2B 22.93%

Net Income 1.6B 16.87%

EPS (Diluted) $11.18

Balance Sheet Metrics

Total Assets 28.0B

Total Liabilities 11.3B

Shareholders Equity 16.7B

Debt to Equity 0.68

Cash Flow Metrics

Operating Cash Flow 2.8B

Free Cash Flow 2.5B

Revenue & Profitability Trend

Biogen Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue	9.7B	9.8B	10.2B	11.0B	13.4B
Cost of Goods Sold	2.3B	2.5B	2.3B	2.1B	1.8B
Gross Profit	7.4B	7.3B	7.9B	8.9B	11.6B
Operating Expenses	4.7B	5.2B	4.6B	5.2B	6.7B
Operating Income	2.2B	1.8B	2.9B	2.8B	4.4B
Pre-tax Income	1.9B	1.3B	3.6B	1.7B	5.0B
Income Tax	273.8M	135.3M	632.8M	52.5M	992.3M
Net Income	1.6B	1.2B	3.0B	1.7B	4.1B
EPS (Diluted)	$11.18	$7.97	$20.87	$10.40	$24.80

Income Statement Trend

Biogen Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	7.5B	6.9B	9.8B	7.9B	6.9B
Non-Current Assets	20.6B	20.0B	14.8B	16.0B	17.7B
Total Assets	28.0B	26.8B	24.6B	23.9B	24.6B
Liabilities
Current Liabilities	5.5B	3.4B	3.3B	4.3B	3.7B
Non-Current Liabilities	5.8B	8.6B	7.9B	8.6B	10.2B
Total Liabilities	11.3B	12.0B	11.2B	12.9B	13.9B
Equity
Total Shareholders Equity	16.7B	14.8B	13.4B	11.0B	10.7B

Balance Sheet Composition

Biogen Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	1.6B	1.2B	3.0B	1.7B	4.1B
Operating Cash Flow	2.8B	1.5B	3.1B	2.3B	4.6B
Investing Activities
Capital Expenditures	-153.7M	-277.0M	342.3M	-258.1M	-424.8M
Investing Cash Flow	-681.7M	-4.1B	1.6B	-526.9M	-481.6M
Financing Activities
Dividends Paid	-	-	-	-	-
Financing Cash Flow	-652.2M	193.6M	-1.7B	-2.1B	-5.3B
Free Cash Flow	2.5B	1.2B	1.1B	3.3B	3.7B

Cash Flow Trend

Biogen Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 12.33

Forward P/E 7.49

Price to Book 1.08

Price to Sales 1.86

PEG Ratio 7.49

Profitability Ratios

Profit Margin 15.07%

Operating Margin 28.05%

Return on Equity 9.19%

Return on Assets 5.43%

Financial Health

Current Ratio 1.44

Debt to Equity 39.00

Beta 0.15

Per Share Data

EPS (TTM) $10.12

Book Value per Share $115.90

Revenue per Share $67.32

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
biib	18.3B	12.33	1.08	9.19%	15.07%	39.00
Eli Lilly and	691.8B	62.76	46.33	77.28%	22.67%	243.61
Johnson & Johnson	364.1B	16.83	4.66	29.45%	24.42%	66.90
Merck & Co	198.5B	11.49	4.12	39.29%	27.27%	71.99
Amgen	146.5B	24.84	23.60	105.67%	17.39%	924.46
Gilead Sciences	132.1B	22.31	6.90	32.65%	20.76%	130.79

Financial data is updated regularly. All figures are in the company's reporting currency.